PVLA

Palvella Therapeutics, Inc.

PVLA · CIK 1583648 · Annual (10-K) · Last 8 years

Financial Trends

Revenue
20172024
Net Income−$17M
20172024
Operating CF−$11M
20172024
Free Cash Flow
20172024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Revenue—$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Cost of Revenue————————
Gross Profit————————
R&D Expense$0.0B$0.0B$0.1B$0.1B$0.0B$0.1B$0.0B$0.0B
SG&A Expense————————
Operating Income$-0.0B$-0.0B$-0.0B$-0.1B$-0.0B$-0.0B$-0.0B$-0.0B
Net Income$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
EPS (Basic)$-7.83$-0.27$-0.45$-0.71————
EPS (Diluted)$-7.83——$-0.71————

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Total Assets$0.1B$0.0B$0.1B$0.2B$0.1B$0.1B$0.1B$0.1B
Current Assets$0.1B$0.0B$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B
Cash & Equivalents$0.1B$0.0B$0.0B$0.1B$0.1B$0.1B$0.1B$0.0B
Total Liabilities$0.0B$0.0B$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B
Current Liabilities$0.0B$0.0B$0.0B$0.1B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.1B$0.0B$0.0B$0.1B$0.0B$0.1B$0.0B$0.0B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Operating Cash Flow$-0.0B$-0.1B$-0.1B$-0.0B$-0.0B$-0.1B$-0.0B—
Investing Cash Flow—$0.0B$-0.0B$-0.0B$0.0B$0.0B$-0.0B—
Capital Expenditures—$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.1B$0.0B$0.0B$0.1B$0.0B$0.0B$0.0B—
← Companies